The Science Behind GLP-1 Drugs and Stomach Problems: Understanding the Link and Lawsuit Implications

Composition and Purpose of GLP-1 Drugs

GLP-1 drugs are designed to help manage type 2 diabetes and, in some cases, support weight loss. Each medication contains ingredients that are similar to a natural hormone in the body known as GLP-1 (glucagon-like peptide-1). This hormone helps regulate blood sugar levels and control appetite.

Different Types of GLP-1 Drugs

Several GLP-1 drugs have been developed, each with specific formulations and uses. They are formulated with a GLP-1 analog — a man-made substance that closely resembles the natural GLP-1 hormone. Just like GLP-1, these analogs help the body control blood sugar levels and manage hunger. By mimicking the actions of the natural hormone, they help regulate how insulin is released and how food is processed in the body.

These medications are classified based on their active ingredients and the way they are administered. Here’s a closer look at each of them:

Ozempic (semaglutide)

Ingredients: The active ingredient in Ozempic is semaglutide, which is a type of GLP-1 analog.

Purpose: Ozempic helps improve blood sugar control in adults with type 2 diabetes and also reduces the risk of major cardiovascular events, such as heart attack and stroke, in people with type 2 diabetes and heart disease.

Approval Date: The FDA approved Ozempic for managing type 2 diabetes on December 5, 2017.

‍

Wegovy (semaglutide)

Ingredients: Wegovy contains semaglutide, similar to Ozempic, and is also a GLP-1 analog.

Purpose: Wegovy is used for weight management in adults and children aged 12 and older with obesity, or those with excess weight and weight-related health problems.

Approval Date: Wegovy was approved for weight management on June 4, 2021.

‍

Rybelsus (semaglutide)

Ingredients: Rybelsus also contains semaglutide, delivered in an oral form rather than an injection.

Purpose: Rybelsus helps improve blood sugar control in adults with type 2 diabetes, offering a non-injection option for those who prefer to take their medication by mouth.

Approval Date: The FDA approved Rybelsus for managing type 2 diabetes on September 20, 2019.

‍

Mounjaro (tirzepatide)

Ingredients: Mounjaro contains tirzepatide, which is a newer type of GLP-1 analog that also mimics another hormone called GIP (gastric inhibitory polypeptide).

Purpose: Mounjaro is used to manage blood sugar levels in adults with type 2 diabetes and helps enhance insulin secretion.

Approval Date: Mounjaro was approved for type 2 diabetes management on May 13, 2022.

‍

Trulicity (dulaglutide)

Ingredients: Trulicity’s active ingredient is dulaglutide, another type of GLP-1 analog.

Purpose: Trulicity improves blood sugar control in adults with type 2 diabetes and helps reduce the risk of heart disease in people with diabetes.

Approval Date: The FDA approved Trulicity for type 2 diabetes management on September 18, 2014.

‍

Saxenda (liraglutide)

Ingredients: Saxenda contains liraglutide, which is a GLP-1 analog.

Purpose: Saxenda is used for weight management and helps individuals with obesity or those who are overweight and have weight-related health issues to lose and maintain weight.

Approval Date: Saxenda was approved for weight management on December 23, 2014.

Severe Gastrointestinal Side Effects

While GLP-1 drugs can be effective for many, they have been linked to several severe gastrointestinal side effects. These issues arise due to the drugs' effects on the digestive system, which can significantly impact quality of life. Understanding these side effects and their scientific impacts can help patients and healthcare providers make informed decisions.

Persistent Vomiting for At Least 4 Weeks

How It Happens: Persistent vomiting refers to continuous or recurrent vomiting lasting for an extended period. GLP-1 drugs slow gastric motility, causing the stomach to empty its contents more slowly, leading to prolonged nausea and vomiting.

‍Impact: Persistent vomiting can lead to dehydration, electrolyte imbalances, and a decline in overall health.

‍Scientific Insight: GLP-1 drugs, including semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro), slow the rate at which the stomach empties. Research indicates that the delayed gastric emptying caused by these drugs leads to persistent vomiting. This effect is documented for semaglutide, liraglutide, and also reported for dulaglutide and tirzepatide in clinical studies.

Gastroparesis

How It Happens: Gastroparesis is a condition where the stomach muscles are weakened or paralyzed, leading to slow or halted movement of food through the stomach. GLP-1 drugs reduce the stomach's ability to contract normally and can slow down the stomach's ability to move food into the intestines.

Impact: Patients with gastroparesis may suffer from persistent nausea, bloating, early satiety, and abdominal pain, which can severely impact their quality of life and nutritional intake.

Scientific Insight: Research indicates that medications like semaglutide and liraglutide contribute to gastroparesis by disrupting normal gastric motility. This association is supported by studies showing that GLP-1 drugs exacerbate symptoms of gastroparesis by further slowing gastric emptying.

Stomach Paralysis / "Frozen Stomach"

How It Happens: Stomach paralysis, or "frozen stomach," involves a severe reduction in the stomach's ability to contract and move food through the digestive tract. GLP-1 drugs significantly slow the rate at which food moves through the stomach. This reduction in gastric motility can lead to a condition where the stomach appears paralyzed or "frozen."

‍Impact: This condition can cause severe abdominal pain, bloating, nausea, and vomiting, severely affecting daily life and overall health.

Scientific Insight: Research has found that semaglutide and other GLP-1 drugs can significantly reduce stomach muscle activity, leading to a "frozen stomach" sensation.

Intestinal Blockage

How It Happens: Intestinal blockage is a condition where the intestines are obstructed, preventing the passage of food or stool. GLP-1 drugs can slow intestinal motility, leading to the accumulation of food and potential blockages within the intestines.

‍Impact: Symptoms include severe abdominal pain, and constipation, and may require emergency medical treatment or intervention.

‍Scientific Insight:  Evidence from research indicates that GLP-1 drugs contribute to intestinal blockages by reducing gut motility. This accumulation of food in the intestines increases the risk of blockages and severe abdominal discomfort

Ileus

How It Happens: Ileus involves a temporary halt in bowel movements, which can be triggered by the reduced motility of the intestines caused by GLP-1 drugs.

‍Impact: This condition can cause severe abdominal pain, bloating, constipation, and vomiting, which require medical treatment to resolve.

‍Scientific Insight: Studies show that these diabetes drugs and GLP-1 receptor agonists can lead to functional intestinal blockages due to their effect on slowing down gastrointestinal movement. This can lead to temporary disruptions in bowel movements and ileus.

Bowel Obstruction

How It Happens: Bowel obstruction involves a blockage in the intestines that affects larger portions of the bowel, leading to severe obstruction. GLP-1 drugs' impact on slowing intestinal transit can cause more significant blockages in the bowel, similar to ileus.

‍Impact: This condition causes severe abdominal pain, inability to pass stool or gas, and abdominal swelling, often requiring urgent medical attention.

‍Scientific Insight: Prolonged use of GLP-1 drugs like semaglutide and liraglutide increases the likelihood of bowel obstructions due to delayed gastrointestinal transit. Studies indicate that these drugs can lead to severe complications by impeding normal bowel function.

FDA Warnings on GLP-1 Drugs

The FDA has updated warning labels for GLP-1 drugs like Ozempic, Wegovy, and Mounjaro to reflect serious gastrointestinal risks, following numerous reports of severe side effects.

The FDA's latest update includes warnings about risks of intestinal blockage, obstruction, and ileus. Specifically, over 18 cases of ileus were reported, along with more than 8,500 total reports of gastrointestinal issues linked to these medications. Among these reports, ileus was cited in 33 cases, which tragically included two deaths.

The updated labeling now aligns with existing warnings for other GLP-1 medications, aiming to ensure that patients and healthcare providers are fully informed about the potential severe gastrointestinal side effects. This move underscores the importance of monitoring and managing these risks effectively.

Why It Matters: Adequate warnings allow patients to take preventive measures and seek timely medical attention, potentially reducing the severity of these side effects. When warnings are insufficient, it can lead to significant health issues and distress for those affected.

Legal Implications and Patient Rights

If you are experiencing severe side effects from GLP-1 drugs, understanding your legal rights is crucial. You have the right to be fully informed about the risks associated with your medication. If you were not adequately warned about these risks, you have the right to seek compensation for any harm suffered.

Taking Action: If you are dealing with side effects from GLP-1 drugs or considering your legal options, our team is here to support you. We are dedicated to investigating these issues, gathering evidence, and holding the drug companies accountable for any failures in providing necessary warnings.

Protecting Your Stomach Health

If you're using GLP-1 drugs and experiencing gastrointestinal symptoms or side effects, it's essential to take proactive steps to protect your health:

1. Regular Monitoring: Keep track of any symptoms and discuss them with your healthcare provider.
2. Dietary Adjustments: Consider making dietary changes to reduce gastrointestinal discomfort.
3. Medical Follow-Up: Regular check-ups can help manage and mitigate side effects.

By staying informed and working closely with your healthcare provider, you can better manage your health and address any issues promptly.

With this knowledge, you’re better equipped to protect your health and assert your rights. By staying informed about potential risks and taking action when needed, you can protect your well-being and advocate for better safety measures.

If you’re dealing with the side effects of GLP-1 drugs or exploring legal options, this information emphasizes the need for increased medication safety and patient protection. Our team is committed to supporting those affected, handling the legal process, and ensuring your rights and health are prioritized every step of the way.